scholarly journals Two Key Proteins of the Vitamin D Endocrine System Come Into Crystal Clear Focus: Comparison of the X-ray Structures of the Nuclear Receptor for 1α,25(OH)2 Vitamin D3, the Plasma Vitamin D Binding Protein, and Their Ligands

2003 ◽  
Vol 18 (5) ◽  
pp. 795-806 ◽  
Author(s):  
Mathew T Mizwicki ◽  
Anthony W Norman
Keyword(s):  
Vitamin D ◽  
Nuclear Receptor ◽  
Vitamin D3 ◽  
Binding Protein ◽  
Endocrine System ◽  
Plasma Vitamin ◽  
Vitamin D Binding Protein ◽  
X Ray

scholarly journals Disruption of microfilament organization in living nonmuscle cells by microinjection of plasma vitamin D-binding protein or DNase I.

1990 ◽  
Vol 87 (14) ◽  
pp. 5474-5478 ◽  
Author(s):  
J. M. Sanger ◽  
G. Dabiri ◽  
B. Mittal ◽  
M. A. Kowalski ◽  
J. G. Haddad ◽  
...  
Keyword(s):  
Vitamin D ◽  
Binding Protein ◽  
Dnase I ◽  
Plasma Vitamin ◽  
Vitamin D Binding Protein ◽  
Nonmuscle Cells

scholarly journals Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants

2019 ◽  
Vol 104 (11) ◽  
pp. 5483-5498 ◽  
Author(s):  
Maria Enlund-Cerullo ◽  
Laura Koljonen ◽  
Elisa Holmlund-Suila ◽  
Helena Hauta-alus ◽  
Jenni Rosendahl ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Binding Protein ◽  
Controlled Trial ◽  
Minor Allele ◽  
Analysis Of Covariance ◽  
High Dose ◽  
Vitamin D Status ◽  
Vitamin D Binding Protein ◽  
Term Infants

Abstract Context Single nucleotide polymorphisms (SNPs) of the vitamin D binding protein encoding the GC (group component) gene affect 25-hydroxyvitamin D (25OHD) concentrations, but their influence on vitamin D status and response to vitamin D supplementation in infants is unknown. Objective To study GC genotype–related differences in 25OHD concentrations and the response to supplementation during a vitamin D intervention study in infants. Design In this randomized controlled trial, healthy term infants received vitamin D3 (10 or 30 μg/d) from 2 weeks to 24 months of age. GC SNPs rs2282679, rs4588, rs7041, and rs1155563 were genotyped. rs4588/7041 diplotype and haplotypes of rs2282679, rs4588, and rs7041 (Haplo3SNP) and of all four SNPs (Haplo4SNP) were determined. Main Outcome Measures 25OHD measured in cord blood at birth and at 12 and 24 months during intervention. Results A total of 913 infants were included. Minor allele homozygosity of all studied GC SNPs, their combined haplotypes, and rs4588/rs7041 diplotype 2/2 were associated with lower 25OHD concentrations at all time points in one or both intervention groups [analysis of covariance (ANCOVA) P < 0.043], with the exception of rs7041, which did not affect 25OHD at birth. In the high-dose supplementation group receiving 30 μg/d vitamin D3, but not in those receiving 10 µg/d, genotype of rs2282679, rs4588, and rs7041; diplotype; and Haplo3SNP significantly affected intervention response (repeated measurement ANCOVA Pinteraction < 0.019). Minor allele homozygotes had lower 25OHD concentrations and smaller increases in 25OHD throughout the intervention. Conclusions In infants, vitamin D binding protein genotype affects 25OHD concentration and efficiency of high-dose vitamin D3 supplementation.

Identification of the sterol- and actin-binding domains of plasma vitamin D binding protein (Gc-globulin)

Biochemistry ◽  
1992 ◽  
Vol 31 (31) ◽  
pp. 7174-7181 ◽  
Author(s):  
John G. Haddad ◽  
Yuan Z. Hu ◽  
Mary A. Kowalski ◽  
Cynthia Laramore ◽  
Kunal Ray ◽  
...  
Keyword(s):  
Vitamin D ◽  
Binding Protein ◽  
Actin Binding ◽  
Plasma Vitamin ◽  
Vitamin D Binding Protein ◽  
Binding Domains

scholarly journals Biochemistry and metabolism of vitamin D / Biohemija i metabolizam vitamina D

2012 ◽  
Vol 31 (4) ◽  
pp. 309-315 ◽  
Author(s):  
Snežana Jovičić ◽  
Svetlana Ignjatović ◽  
Nada Majkić-Singh
Keyword(s):  
Vitamin D ◽  
Cytochrome P450 ◽  
Vitamin D3 ◽  
Mammalian Cells ◽  
Parent Compound ◽  
Endocrine System ◽  
Target Cells ◽  
Plasma Vitamin ◽  
Endocrine Gland ◽  
Target Organs

Summary Vitamin D is not technically a vitamin, since it is not an essential dietary factor. It is rather a prohormone produced photochemically in the skin from 7-dehydrocholesterol. Vitamin D and its metabolites may be categorized as either cholecalciferols or ergocalciferols. Cholecalciferol (vi - tamin D3) is the parent compound of the naturally occurring family and is produced in the skin from 7-dehydrocholesterol on exposure to the ultraviolet B portion of sunlight. Vitamin D2 (ergocalciferol), the parent compound of the other family, is manufactured by irradiation of ergosterol produced by yeasts and its potency is less than one-third of vitamin D3’s potency. The steps in the vitamin D endocrine system include the following: 1) the photoconversion of 7- dehydrocholesterol to vitamin D3 in the skin or dietary intake of vitamin D3; 2) metabolism of vitamin D3 by the liver to 25-hydroxyvitamin-D3 [25(OH)D3 ], the major form of vitamin D circulating in the blood compartment; 3) conversion of 25(OH)D3 by the kidney (functioning as an endocrine gland) to the hormone 1,25-dihydroxyvitamin D3 [1,25(OH)2D3 ]; 4) systemic transport of the dihydroxylated metabolite 1,25(OH)2D3 to distal target organs; and 5) binding of 1,25(OH)2D3 to a nuclear receptor (VDR) at target organs, followed by generation of appropriate biological responses. The activation of vitamin D to its hormonal form is mediated by cytochrome P450 enzymes. Six cytochrome P450 (CYP) isoforms have been shown to hydroxylate vitamin D. Four of these, CYP27A1, CYP2R1, CYP3A4 and CYP2J3, are candidates for the enzyme vitamin D 25-hy - droxylase that is involved in the first step of activation. The highly regulated, renal enzyme 25-hydroxyvitamin D-1a-hy - dro xylase contains the component CYP27B1, which completes the activation pathway to the hormonal form 1,25(OH)2D3. A five-step inactivation pathway from 1,25(OH)2D3 to calcitroic acid is attributed to a single multifunctional CYP, CYP24A1, which is transcriptionally in du - ced in vitamin D target cells by the action of 1,25(OH)2D3. An additional key component in the operation of the vitamin D endocrine system is the plasma vitamin D binding protein (DBP), which carries vitamin D3 and its metabolites to their metabolism and target organs. DBP is a specific, high-affinity transport protein. It is synthesized by the liver and circulates in great excess, with fewer than 5% of the binding sites normally occupied. 1,25(OH)2D3, acts as a ligand for a nuclear transcription factor, vitamin D receptor - VDR, which like all other nuclear receptors, regulates gene transcription and cell function. The widespread presence of VDR, and the key activating (1a-hydroxylase, CYP27B1) and inactivating (24-hydroxylase, CYP24A1) en - zy mes in most mammalian cells means that the cells in these tissues have the potential to produce biological res pon ses, depending on the availability of appropriate amounts of vi - tamin D3. Thanks to this widespread presence of elements of vitamin D endocrine system, its biological features are being recognized outside bone tissue, i.e. calcium and pho - sphate metabolism.

scholarly journals Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2supplementation

2013 ◽  
Vol 12 (1) ◽  
Author(s):  
Hataikarn Nimitphong ◽  
Sunee Saetung ◽  
Suwannee Chanprasertyotin ◽  
La-or Chailurkit ◽  
Boonsong Ongphiphadhanakul
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Binding Protein ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Selective inhibition of the C5a chemotactic cofactor function of the Vitamin D binding protein by 1,25(OH)2 Vitamin D3

2006 ◽  
Vol 43 (8) ◽  
pp. 1109-1115 ◽  
Author(s):  
Anisha B. Shah ◽  
Stephen J. DiMartino ◽  
Glenda Trujillo ◽  
Richard R. Kew
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Binding Protein ◽  
Selective Inhibition ◽  
Vitamin D Binding Protein

Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants

2015 ◽  
Vol 28 (9-10) ◽  
Author(s):  
Corrine Hanson ◽  
Elizabeth Lyden ◽  
Amy Nelson ◽  
Melissa Thoene ◽  
Julie Wagner ◽  
...  
Keyword(s):  
Vitamin D ◽  
Bone Mineral Content ◽  
Bone Mineral ◽  
Premature Infants ◽  
Vitamin D3 ◽  
Mineral Content ◽  
Binding Protein ◽  
Vitamin D Binding Protein ◽  
Vitamin D Levels ◽  
Free Vitamin D

AbstractThe objective of this study was to evaluate the relationship between 25(OH)D, Vitamin D Binding Protein (DBP), and free vitamin D in premature infants.Thirty-two infants <32 weeks’ gestation were randomized to two different levels of vitamin D3 supplementation (400 vs. 800 IU/day). 25(OH)D levels were measured by LC-MS/MS; DBP was measured by validated ELISA. Free vitamin D was calculated using molar ratios of 25(OH)D and DBP. The Wilcoxon signed rank test was used to compare DBP, free D and 25(OH)D levels; Spearman’s correlation coefficients were used to assess correlations.The mean gestational age at birth was 30.5 weeks; mean birth weight was 1405 g. Mean 25(OH)D levels at birth were 17.3 ng/mL; DBP levels were 297 mg/L, and estimated free vitamin D levels were 18.9. There was a statistically significant change in 25(OH)D levels after 8 weeks (24.6 vs. 39.1 ng/mL in the 400 vs. 800 group, respectively, p=0.02). DBP levels from birth to 8 weeks showed a statistically significant decrease (267 vs. 208, p=0.04). Estimated free 25(OH)D concentrations increased over the study period, from 18.9 at birth to 64.7 at 8 weeks of age (p=0.0001). Free vitamin D levels at birth were associated with global DEXA bone mineral content at discharge from the NICU (r=0.58, p=0.05).Supplementation with vitamin D3 increased the free portion of the vitamin D metabolite, providing increased bioavailable substrate. Improved free vitamin D levels may improve measurable outcomes such as bone mineral content and deserve further evaluation.

Sign in / Sign up

Export Citation Format

Share Document